(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Noctourism: the new safari travel trend that's changing the wildlife we can photograph in Africa - 2Old photos misrepresented as aftermath of political party supporters' brawl in Bangladesh
- 3Concern for couple jailed in Tehran as British embassy closes
- 4OpenAI launches ChatGPT Health to connect medical records, wellness apps
- 5Winter solstice 2025 marks the shortest day of the year in the Northern Hemisphere today
- 6 Trail blazing Bicycles for Rough terrain Undertakings
- Reviving Your Home with Nutritious Indoor Plants
- Israel and Iran continue tit-for-tat attacks
- 3 Italian City Cars That Outsmarted Regulations and Rivals
- Clocks to go forward one hour in Europe as summer time starts
- NASA’s history-making moon mission aims to send the first woman and person of color to deep space
- How do my eyes adjust to the dark and how long does it take?
- Step by step instructions to Protect Your Speculations with Cd Rates
- Florence's Uffizi Gallery moves treasures to safety after cyberattack
